Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its complete financial results for the fourth quarter and the entirety of fiscal year 2025. This announcement follows a notably strong third-quarter performance that has raised expectations. The key question for shareholders is whether the biopharmaceutical firm can sustain its recent positive earnings momentum.

• Earnings Release: February 26, 2026 (after U.S. market close).
• Q3 2025 Recap: Earnings per share of $0.21, against consensus estimates of $0.09.
• Executive Compensation: 14,750 Restricted Stock Units (RSUs) granted to two new hires.
• Price Targets: A wide analyst range, from $3.50 to $7.00.
• Market Sentiment: Short interest stands Read more...